Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T13:30:18.587Z.
Calculation as of: 2026-10-06T13:30:18.587Z.
Quote observation: 2026-10-06T13:30:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 79e645a94fbd5e366445fb8f0b2dfca38265e5d6ea8975ca37c6e7b4421e0c07
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Aardvark Therapeutics, Inc. Common Stock
Market Cap
$115.55M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$111.17M
EBITDA Yield
N/A
TTM Avg
6.77%
3Y Avg
6.77%
5Y Avg
6.77%
Market Cap
$118.50M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $115.55M | N/A | N/A | N/A | N/A |
| Coya Therapeutics, Inc. (COYA)vs › | $114.00M | N/A | N/A | N/A | N/A |
| LENZ Therapeutics, Inc. (LENZ)vs › | $112.56M | N/A | N/A | N/A | N/A |
| Genelux Corporation (GNLX)vs › | $115.69M | N/A | N/A | N/A | N/A |
| Black Diamond Therapeutics, Inc. (BDTX)vs › | $111.17M | N/A | 6.77% | 6.77% | 6.77% |
| Foghorn Therapeutics Inc. (FHTX)vs › | $117.43M | N/A | N/A | N/A | N/A |
| Caribou Biosciences, Inc. (CRBU)vs › | $118.02M | N/A | N/A | N/A | N/A |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $118.50M | N/A | N/A | N/A | N/A |
| Immunic, Inc. (IMUX)vs › | $109.93M | N/A | N/A | N/A | N/A |
| BGM Group Ltd. (BGM)vs › | $118.63M | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
